AccuMetab™ Human CYP2C9∗ 3 Enzyme, Catalytically Active with Cytochrome b5

CAT#: ITS-0426-YL74
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Enhanced CYP2C9∗ 3 variant for high-activity pharmacogenetic Phase I profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
The addition of Cytochrome b5 helps stabilize the structurally compromised CYP2C9∗ 3 variant, allowing for reliable, reproducible in vitro kinetics. This allows researchers to accurately quantify the precise degree of metabolic impairment caused by this specific human polymorphism.
Key Features
Cytochrome b5 supplemented to rescue *3 impairment; Accurately quantifies exact metabolic loss degrees; Essential for predicting life-threatening patient toxicities; Supplied in controlled, low-reductase formats
Applications
Enhanced Drug Metabolism Studies, MetID, DDI
Research Areas
ADME; Pharmacogenetics; DDI
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry